Scpp.Wa
SCPP.WA operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Business. SCPP.WA operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SCPP.WA operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
SCPP.WA has a current ratio of 13.06, indicating strong short-term liquidity, but its free cash flow is negative at -57.62 million PLN, suggesting ongoing cash outflows from operations. The company's debt-to-equity ratio is 0.01, reflecting a low leverage position, with long-term debt amounting to 2.15 million PLN. Despite this, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
The company's profitability metrics are negative, with a return on equity of -28.54% and a return on assets of -23.66%, indicating poor returns on both equity and total assets. Gross profit is -3.64 million PLN, and operating income is -47.28 million PLN, highlighting significant operational inefficiencies. These figures are below the industry median for profitability, suggesting underperformance relative to peers.
SCPP.WA's revenue is concentrated in a single segment, with no disclosed geographic diversification, increasing exposure to regional economic or regulatory risks. The company's revenue is entirely derived from its core pharmaceutical and medical research activities, with no material diversification across product lines or markets.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year and no clear guidance for the next fiscal year. Analysts have assigned a mean recommendation of 2.00, indicating a "hold" rating, with no strong buy or sell recommendations. The company's operating cash flow is negative at -46.11 million PLN, and capital expenditures are -13.39 million PLN, suggesting ongoing investment in operations despite negative cash flows.
The company faces moderate liquidity risk due to its negative free cash flow and negative net cash position after debt. Dilution risk is low, with no near-term pressure from share issuance or dilutive events. The company has not disclosed any recent material events, such as regulatory changes, product launches, or strategic partnerships, that would significantly impact its operations.
- SCPP.WA has strong short-term liquidity but is experiencing significant negative cash flows from operations.
- The company's profitability metrics are negative, with poor returns on equity and assets.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Analysts have assigned a "hold" rating, with no strong buy or sell recommendations.
- The company's liquidity risk is moderate, and dilution risk is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -17,20 |
| Revenue | —no estimate | —no estimate | 2,5M PLN |
| Operating income | —no estimate | —no estimate | -68,6M PLN |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SCPP.WA Market data — financials · 2026-05-29
- Scope Fluidics SA Market data — analyst estimates · 2026-05-29